{
    "physical_examinations": [
        {
            "date": "Not specified",
            "vital_signs": "Not specified",
            "relevant_findings": "Height: 120.4 cm (-7.44 sd), Weight: 23.0 kg (-6.49 sd), Body mass index: 16.2 kg/m² (-1.9 sd), Upper-to-lower segment ratio: 1.07, Triceps skinfold thickness: 6.0 cm (-0.93 sd), Subscapular skinfold thickness: 7.6 cm (-0.0 sd). Neurological examination: severe bilateral sensorineural deafness, mild myopia. Mild dysmorphic features: micrognathia, bilateral ptosis, low hairline, bilateral clinodactyly, left-sided single palmar crease.",
            "changes_over_time": "Not specified"
        },
        {
            "date": "Not specified",
            "vital_signs": "Not specified",
            "relevant_findings": "Baseline BMD: 0.58 g/cm² (sd score -4.88), Osteocalcin: 8.3 ng/mL pretreatment, Bone specific alkaline phosphatase: 36.5 U/L pretreatment. After 6 months: Osteocalcin 21.7 ng/mL, Bone specific alkaline phosphatase 82.2 U/L.",
            "changes_over_time": "Osteocalcin and bone specific alkaline phosphatase increased significantly after 6 months on rhIGF-I therapy."
        }
    ]
}